
Daewoong Pharmaceutical announced Monday that its smart patient monitoring system, thynC (Think Better, Sync Smarter), has become the first domestically developed digital health care device in Korea to receive insurance reimbursement approval.
The company held a press conference in central Seoul, where it introduced its broader digital health care vision, aiming to establish a more efficient and cost-effective medical checkup system for both patients and hospitals.
Cho Byung-ha, head of Daewoong Pharmaceutical’s marketing division, opened the floor by insisting that the rapid expansion of digital health care in medical settings has become a global trend. “By advancing digital health care technology and incorporating AI-powered disease prediction solutions like thynC, we aim to enhance the overall healthcare environment in the country,” he said.
Co-developed by Seers Technology and Daewoong Pharmaceutical and distributed by Daewoong Pharmaceutical, thynC is a comprehensive remote patient monitoring system consisting of wearable biosensors, a monitoring management application and AI algorithms. These wearable biosensors, when attached to a patient, measure key vital signs such as electrocardiogram, body temperature and oxygen saturation. The AI system processes this data and provides real-time insights to medical staff, allowing them to remotely monitor patients’ conditions.
Cho emphasized that the company will continue refining inpatient health management across multiple medical departments, including cardiology, neurology, pulmonology, surgery, emergency medicine and oncology. “Our ultimate goal is to improve patient monitoring efficiency for health care professionals,” he said.
One of the most significant advantages of thynC is its ability to eliminate the need for medical staff to conduct frequent in-person patient checks in hospital wards, making remote monitoring possible. This is particularly beneficial for non-face-to-face health care settings, such as those required during the COVID-19 pandemic.
“The service can detect critical conditions such as cardiac arrest, sepsis and falls, enabling immediate medical intervention and significantly improving patient safety,” said Lee Young-shin, CEO of Seers Technology. He stressed that, amid the current shortage of medical residents and nurses in Korea, thynC would play a vital role in enhancing hospital efficiency and improving the quality of patient care.
Lim Hong-euy, a cardiologist at Chung-Ang University Hospital in Gwangmyeong, Gyeonggi Province, shared his findings from real-world studies using thynC.
“Only 1.7 percent of Korea’s 700,000 hospital beds are in intensive care units with automated real-time monitoring, while the remaining 99 percent of general ward beds still rely on manual nurse rounds,” he explained. “Some 20 to 30 percent of inpatients fall into a critical category — too ill for general wards but not requiring ICU care. With real-time monitoring through thynC, we can significantly reduce mortality risks for these patients.”
Meanwhile, Daewoong Pharmaceutical also announced plans to integrate Sky Labs’ ring-type blood pressure monitor Cart BP with thynC within the first half of the year. Currently, thynC is being used in 10 hospitals across the country, with plans to expand its adoption to major general hospitals and mid-sized hospitals.
Looking ahead, Daewoong Pharmaceutical plans to launch a digital health care screening package in the latter half of the year, further expanding its health checkup services through thynC.
link